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We present a 43-year-oldman with aortic root dilation, mitral valve prolapse, andmarfanoid appearance, who presented with acute
onset left leg pain. He underwent a Doppler ultrasound that revealed left popliteal artery aneurysm with thrombus. CT angiogram
showed bilateral popliteal artery aneurysms. After repairing of his left popliteal artery aneurysm, he was sent for genetic evaluation.
He was diagnosed with Marfan syndrome (MFS) based on the revised Ghent criteria and then underwent FBN1 sequencing and
deletion/duplication analysis, which detected a novel pathogenic variant in gene FBN1, denoted by c.5872 T>A (p.Cys1958Ser).MFS
is a connective tissue disorder with an autosomal dominant inheritance due to pathogenic variants in FBN1 that encodes Fibrillin-
1, a major element of the extracellular matrix, and connective tissue throughout the body. MFS involves multiple systems, most
commonly the cardiovascular, musculoskeletal, and visual systems. In our case we present a rare finding of bilateral popliteal artery
aneurysms in a male patient with MFS.
1. Background
MFS is a genetic connective tissue disorderwith an autosomal
dominant inheritance that involves multiple systems, most
commonly the cardiovascular, musculoskeletal, and ocular
systems [1]. It is caused by pathogenic variants in FBN1
that encodes Fibrillin-1, a major element of the extracellular
matrix, and connective tissue throughout the body [2].Due to
the improved survival and longer life expectancy of patients
with MFS, less common phenotypic features continue to be
observed [3]. MFS is diagnosed based on Ghent criteria,
which takes into account clinical manifestations, genetic
testing, and family history [4]. In this report we present a
male patient with clinical features ofMFS, a novel pathogenic
variant in FBN1, and the unusual finding of bilateral popliteal
aneurysms.
2. Case Presentation
Our proband is a 43-year-old male of northern European
descent who initially presented with acute onset left leg
cramping pain that lasted for several days. The pain was
associated with numbness in his left leg and nausea. His
past medical history was significant for mitral valve prolapse,
aortic root dilation umbilical hernia left anterior cruciate
ligament (ACL) rupture, and severe myopia corrected with
LASIK surgery. Family history revealed rheumatic heart
disease in his mother, necessitating mitral valve repair due
to mitral valve prolapse with severe regurgitation. Upon
examination, his popliteal arterial pulses were 4+ bilateral,
bounding. His height was 196 cm, with an increased arm
span-height ratio of 1.07. He had a mild pectus carinatum
deformity, mild scoliosis positive wrist and thumb sign, pes
planus, and mild skin striae. A Doppler ultrasound was
performed by his primary care physician (PCP), which ruled
out deep venous thrombosis (DVT); however, it revealed
a large left popliteal artery aneurysm with thrombus that
measured 6.3 × 3.1 × 3.4 cm. He underwent a CT angiogram
that showed normal abdominal aorta as well as common
iliac arteries. However it showed bilateral popliteal artery
aneurysms measuring 3.6 × 4 cm in the left side and 3 ×
2.8 cm in the right side (Figure 3). After repairing of his left
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Table 1
Feature Value
Wrist and thumb sign 3
Pectus carinatum deformity 2
Hindfoot deformity 2




Mitral valve prolapse 1
Total 12
popliteal artery aneurysm with bovine carotid interposition
via posterior approach, he was sent for cardiac and genetic
evaluations. He underwent a MRI exam of the heart with
and without intravenous gadolinium contrast administration
(Figure 2) which showed mild bileaflet mitral valve prolapse
and aortic root dilation (measuring 46mm at the level of
the sinuses of Valsalva). The patient has been prescribed
metoprolol tartrate and losartan to control his aortic root
disease and was to undergo elective aortic repair when the
aortic dimension becomes near to or reaches 50mm. A
diagnosis ofMarfan syndromewasmade based on the revised
Ghent criteria as the proband had aortic root dilation (𝑍-
score: 3.72) and a systemic score of 12 (Table 1). His diagnosis
was further confirmed after undergoing FBN1 sequencing
and deletion/duplication analysis, which detected a novel
pathogenic variant in gene FBN1, denoted by c.5872 T>A
(p.Cys1958Ser) (Figure 1).
3. Discussion
Arterial aneurysms aremost commonly caused by atheroscle-
rotic disease, especially in elderly patients aged over 60.
Other etiologies, such as connective tissue disorders, should
be investigated in younger patients such as ours [5, 6].
Fibrillin-1 microfibrils, through interactions with elastin and
other proteins, provide structure to elastic and nonelastic
connective tissues [7, 8]. In addition to the architectural func-
tions, Fibrillin-1 plays an important role in regulating TGF-
𝛽 complexes in the extracellular matrix. TGF-𝛽 signaling
controls various processes at the cellular level, such as cellular
growth, differentiation, and apoptosis [9, 10].When Fibrillin-
1 is defective, it disrupts the normal architecture of connective
tissues. Elastic fibers, found in tissues such as aortic media,
become disorganized and fragmented resulting in the loss of
elastic properties which causes the vessels to be less compliant
and more prone to dilation and aneurysm formation [10, 11].
Pathogenic variants are identified in 72–93% of individ-
uals fulfilling a clinical diagnosis of MFS based on Ghent
nosology [12, 13]. The likelihood of detecting a pathogenic
variant decreases for those individuals not meeting Ghent
criteria [12]. Large intragenic deletions in the FBN1 gene have
been detected in approximately 2% of individuals with MFS
who did not have a pathogenic variant identified by sequence
analysis [14].
In our case a pathogenic variant has been identified in
the FBN1 gene.The C1958S variant has not been published as
pathogenic or been reported as benign to our knowledge.The
C1958S variant is a nonconservative amino acid substitution,
which is likely to impact secondary protein structure as these
residues differ in polarity, charge, and size. This substitution
occurs at a position that is conserved across species and
in silico analysis predicts this variant is probably damaging
to the protein structure or function. Additionally, C1958S
affects a Cysteine residue within a calcium-binding EGF-like
domain of the FBN1 gene, whichmay affect disulfide bonding
and is predicted to alter the structure and functions of the
protein. Cysteine substitutions in the calcium-binding EGF-
like domains represent the majority of pathogenic missense
changes associated with FBN1-related disorders [2]. Further-
more, other missense variants at the same residue (C1958Y,
C1958R) have also been reported in published literature in
association with FBN1-related disorders, including assumed
de novo occurrences for both variants, supporting the func-
tional significance of this residue [15–17]. Finally, this variant
has not been observed in large population cohorts such as the
ExAC (Exome Aggregation Consortium) database [18–20].
Based on these data, ACMG variant classification guidelines
[21] classify our variant as pathogenic (IIIa) (evidence: PM2,
PS1, PM5, PP3, BS4, and PM1).
Peripheral vascular aneurysms in patients with Marfan
syndrome have been reported on rare occasions [5, 22–24].
Bilateral popliteal aneurysms inMFS have been described on
two occasions before [5, 23], but in one of these studies, it was
believed that autosomal dominant polycystic kidney disease
(ADPKD) was the main contributor to this manifestation
[5]. In our case the patient did not have any other medical
conditions besides his MFS diagnosis. Popliteal aneurysms
should be properly investigated and repaired, as they can
result in serious complications such as thrombus formation
or rupture.
Based on history, the mother’s mitral valve prolapse with
severe regurgitationwas attributed to rheumatic valve disease
rather than a genetic connective tissue disorder. However, it
is still a very likely possibility as her son has a confirmed
diagnosis ofMFS. She is yet to undergo the FBN1 sequencing.
Due to its rarity in MRS we do not recommend screening
for peripheral vascular aneurysms in patients diagnosed with
MRS as we do not think it is a cost-effective approach.
However, we do recommend that patients with popliteal or
other peripheral aneurysms, especially those who are rela-
tively young and without risk factors, should undergo further
clinical and genetic assessment in order to confirm/exclude
the possibility of inherited connective tissue disorders.
In summary we describe the case of a 43-year-old male
with a novel pathogenic variant in FBN1 causing Marfan
syndrome with the rare phenotype of bilateral popliteal
aneurysms. Further advancements in medical genetics will




ACL: Anterior cruciate ligament
ADPKD: Autosomal dominant polycystic kidney disease.
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Figure 1: DNA chromatogram demonstrating heterozygous c.5872T>A variant in FBN1.
Figure 2: MRI of the heart with and without intravenous gadolin-
ium contrast administration.
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